Insight journal - Deals and alliances

Current Agreements Deals Update: November 2011

Posted on 10 November 2011

Tags: , , , ,

Welcome to the November 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in October 2011. 

 

Deal of the month

Development agreement for miR-208 and miR-15/195 plus additional target

Servier, MiRagen - October 18, 2011  

Agreement for advancing the research, development and commercialization of three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease more

Breaking news...

Collaborative R&D and co-development agreement for Nanobodies against two targets in osteoarthritis  

Merck Serono, Ablynx - November 9, 2011

Termination agreement for Bydureon (exenatide) once-weekly

Eli Lilly, Amylin - November 8 2011

For more breaking deals as they are announced, visit:http://www.currentagreements.com

What's new...

New flexible subscription options now available

Current Agreements is now available on a number of flexible subscription options - fees from USD1,000 for a single user.

For further details of What's new at Current Agreements, visit here.

 

Month In Review

Welcome to the November 2011 edition of Current Agreements Deals Update.

This month we are providing you with an overview of deal making activity in the life sciences, covering partnering and M&A in October 2011.

As we move into the fall, partnering activity appears to continue at a good pace. A total of 307 partnering deals were announced during the month, with the top deal by value being the contract service and supply agreement for BioThrax between Emergent Biosolutions and the US government. The deal had a headline value of USD1250 million. Further details can be viewed here.

M&A also saw significant activity with 44 deals announced, with the leading deal being the acquisition of PPD by The Carlyle Group and Hellman & Friedman for USD3.9 billion. Full details here.

Our sister company, Current Partnering has just published a new report:

In addition, with the emerging role of personalized medicine in recent dealmaking we have published a series of reports:

Our newly launched Current Partnering website showcases the leading partnering, M&A and financing deals by value.

To see the leading deals of 2011 so far, view the set of Scorecards for 2011: Top partnering deals 2011 | Top M&A deals 2011 - check them out.

We have also recenly updated our highly popular Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report -further details here.

We welcome your comments and feedback on this newsletter. We also welcome contact from any company that has a deal not already announced by press release, allowing us to add non-publicized deals to the database.

Regards

Steve Poile

 

The Top Ten

The following are the top 10 partnering deals and alliances by value, as announced in October 2011.

1. Contract service and supply agreement for BioThrax -Emergent BioSolutions, US Government - USD1250m

2. Development agreement for miR-208 and miR-15/195 plus additional target Servier, miRagen Therapeutics - USD1000m

3. Collaborative R&D and licensing agreement for oral Syk inhibitors - Biogen Idec, Portola Pharmaceuticls - USD553m

4. Collaborative R&D agreement for cancer therapies -Servier, Galapagos - USD345m

5. Licensing agreement for GMI-1070 - Pfizer, GlycoMimetics - USD340m

6. Asset purchase agreement for Middle East and African business - Cephalon, Acina Pharma - USD110m

7. Contract service agreement for preclinical services for the development of biopharmaceutical products for infectious diseases - NIAID, SAIC - USD102m

8. Collaborative R&D and licensing agreement for botulinum toxin therapeutics - Ipsen, Syntaxin - USD99m

9. Supply and contract service agreement for ProBeam system - Varian Medical Systems, Scripps Proton Therapy Center - USD88m

10. Contract agreement for facility renovation - Merck & Co, Skanska - USD80m

Full details of each deal available at Current Agreements*
*Subscription required

 

Bigpharma Partnering

October saw 53 partnering deals announced where bigpharma were at least one of the parties to the deal. This is up from the 31 deals recorded in the previous month.

Pfizer led the way during October with eight partnering deals - with partners Medco Health Solutions/United BioSource, Adams and Knight, Humana, deCode Genetics, Glycomimetics, Exonhit Therapeutics, Puma Biotech, and MedImmune.

The deal with MedImmune focuses on the licensing of tremelimimab (CP-675, 206). MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies.

Further details are available at Current Agreements.

 

Deal Update Articles

Recent deals and alliances in life sciences - here's our take:

miRagen and Servier in cardiovascular tie up could be worth $1 billion

The agreement is for advancing the research, development and commercialization of three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195) and one additional target yet to be identified, for cardiovascular disease.

Abbott split sparks partnering and M&A fever

The recent announcement that Abbott is to split into two companies has resulted in many speculating that the new pharma business will either be a new partnering powerhouse or acquisition target, depending upon which analyst you listen to.

PPD acquired by private equity in USD3.9 billion deal

Private equity has further demonstrated its appetite for acquiring CRO businesses in anticipation of competing for big development contracts being offered by bigpharma.

 

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new2gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif